Stocks · News reference
Pharming Group shares are trading higher after the company announced the commercial launch of Joenja in Japan for adult and pediatric patients with activated PI3K delta syndrome aged 4 years and older.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Pharming Says FDA Grants Priority Review For Joenja In Children With APDS Weighing 13 To 27 Kg; Decision Due January 30, 2027
HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and maintains $37 price target.
Pharming Wins FDA Approval For Joenja In Children Ages 4 To 11 Who Weigh At Least 27kg, With New 40mg/50mg Twice-Daily Doses Expected In October
FDA approval expands Joenja indication to include children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) ages 4 to 11 who weigh at least 27kgNewly approved Joenja doses are expected to be